Lenvervimab

Lenvervimab is a monoclonal antibody designed for the treatment of COVID-19. It was developed by Celltrion, a South Korean biopharmaceutical company. Lenvervimab is also known by its developmental code name, CT-P59.

Mechanism of Action

Lenvervimab works by binding to the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This mechanism of action is similar to other monoclonal antibodies used in the treatment of COVID-19.

Clinical Trials

Lenvervimab has undergone Phase I, Phase II, and Phase III clinical trials. The results from these trials have shown that Lenvervimab is effective in reducing the severity of COVID-19 symptoms and the duration of the disease.

Approval

In February 2022, Lenvervimab was granted conditional approval by the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of COVID-19.

Side Effects

As with all medications, Lenvervimab can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and diarrhea.

See Also

• COVID-19 pandemic
• COVID-19 vaccine
• Monoclonal antibodies for COVID-19

Lenvervimab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia